Top Markets
#1 Black Phoenix Black Phoenix +166.58%
#2 Islamic Coin Islamic Coin +158.26%
#3 Glidr Glidr +84.34%
#4 Test Test +23.21%
#5 Cryptopia Cryptopia +21.17%
#6 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.42%
#7 Quantum Resistant Ledger Quantum Resistant Ledger +15.72%
#8 DOVU DOVU +11.66%
#9 MarsCoin MarsCoin +11.25%
#10 Wrapped Bitcoin (PulseChain) Wrapped Bitcoin (PulseChain) +11.04%
Coin of the day
Black Phoenix Black Phoenix
Settings
Language
ENGLISH
Currency
USD
Theme
Arno Therapeutics, Inc. Arno Therapeutics, Inc.

Arno Therapeutics, Inc.

ARNI
Rank in Stocks #42094
Arno Therapeutics, Inc., headquartered in Flemington, New Jersey, operates as a... Arno Therapeutics, Inc., headquartered in Flemington, New Jersey, operates as a biopharmaceutical enterprise focused on discovering and advancing treatments for cancer and other severe health conditions. The company's developmental portfolio includes several key compounds: Onapristone, a type 1 anti-progestin hormone blocker, is currently undergoing Phase I/II clinical trials. This therapeutic is being investigated for its efficacy in treating various solid tumors, such as breast and endometrial cancers in post-menopausal women, and advanced castration-resistant prostate cancer in men. AR-12, an orally administered cancer therapy, has successfully completed Phase I clinical studies for solid tumors and hematological malignancies. Additionally, it is in pre-clinical development for potential applications against a range of microbial targets. AR-42, another innovative oral cancer treatment, is involved in a Phase I investigator-initiated clinical study, targeting both hematological malignancies and solid tumors. To support its research and development efforts, Arno Therapeutics has established licensing agreements with Invivis Pharmaceuticals, Inc., the Regents of the University of Minnesota, and the Ohio State University Innovation Foundation. The company also holds a co-development partnership with Leica Biosystems Newcastle Ltd.
Share Price
$0.0001
Last synced: 2026-08-11
Market Cap
$4.94K
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade Arno Therapeutics, Inc. (ARNI)

Category

Healthcare
Operating Margin for Arno Therapeutics, Inc. (ARNI)
Operating Margin as of 2026 TTM: 0.00%
According to Arno Therapeutics, Inc. latest financial reports and stock price the company's current Operating Margin (TTM) is 0.00%. At the end of 2026 the company had an Operating Margin of 0.00%.
Operating Margin history for Arno Therapeutics, Inc. from 2026 to 2026
Operating Margin at the end of each year
Year Operating Margin Change
Not enough data for the provided dates.
Operating Margin for similar companies or competitors
Company Operating Margin Operating Margin Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
38.97% -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
28.81% -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00% -
CH
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
31.23% -
BE
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
0.00% -
KR
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.